AstraZeneca To Cease EVOLVE-Lung02 Phase III Trial Of Volrustomig + Chemotherapy In MNSCLC
AstraZeneca said it will stop the eVOLVE-Lung02 Phase III trial of volrustomig plus chemotherapy in metastatic NSCLC after an Independent Data Monitoring Committee review. The trial enrolled 895 patients across 25 countries. AstraZeneca said the combination was unlikely to meet progression-free survival or overall survival endpoints in PD-L1 negative (<1%) patients. Other volrustomig Phase III trials continue.
How this was made
The 30-second read
Why it matters
Discontinuing eVOLVE-Lung02 removes a first-line mNSCLC development path in PD-L1 negative (<1%) patients and signals the combination is unlikely to achieve the trial’s progression-free survival and overall survival endpoints.
Market read
This is a concrete clinical-development setback for AZN’s volrustomig program in a specific mNSCLC subgroup, with other Phase III studies still ongoing.
What to watch
The trial enrolled 895 patients across 25 countries and the decision is based on PD-L1 negative (<1%) primary analysis; outcomes in other PD-L1 strata or tumor types are not addressed here.
Background
AstraZeneca’s volrustomig is a dual checkpoint inhibitor bispecific antibody targeting PD-1 and CTLA-4, evaluated in multiple tumor types.
Ticker impact
AstraZeneca is discontinuing the eVOLVE-Lung02 Phase III trial of volrustomig plus chemotherapy after the IDMC found it unlikely to meet dual primary endpoints.
Likely negative near-term sentiment for AZN tied to oncology pipeline expectations, with follow-through risk until investors re-rank volrustomig’s remaining trials.
The article cites an IDMC recommendation after planned review, stating the combination is unlikely to meet progression-free survival and overall survival endpoints in the primary PD-L1 negative (<1%) population. Other Phase III volrustomig trials continue, which may partially offset the impact.
Market effects
Highlights checkpoint-bispecific development risk in lung cancer, potentially affecting sentiment for similar immuno-oncology strategies.
Limited direct regional spillover; primarily impacts European pharma sentiment around oncology pipeline durability.
Global read-through for PD-1/CTLA-4 bispecific combinations in PD-L1 low or negative mNSCLC.
Counterpoint
Because other Phase III volrustomig trials (cervical cancer, head and neck squamous cell carcinoma, mesothelioma) continue, investors may treat this as a targeted failure rather than a platform-wide setback.
Key entities
- companyAstraZeneca Plc
Announced discontinuation of the eVOLVE-Lung02 Phase III trial for volrustomig plus chemotherapy in metastatic NSCLC.
- drug_candidatevolrustomig
Dual checkpoint inhibitor bispecific antibody for coordinated PD-1 and CTLA-4 blockade.
- committeeIndependent Data Monitoring Committee (IDMC)
Recommended discontinuation after planned review of trial data.
